AN2 Therapeutics, Inc.
ANTX
$5.64
-$0.34-5.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.16% | -1.01% | -24.08% | -12.74% | 7.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.39% | -8.55% | 8.24% | -14.71% | -54.56% |
| Operating Income | -23.39% | 8.55% | -8.24% | 14.71% | 54.56% |
| Income Before Tax | -26.66% | 5.83% | -15.79% | 26.63% | 55.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.66% | 5.83% | -15.79% | 26.63% | 55.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.66% | 5.83% | -15.79% | 26.63% | 55.23% |
| EBIT | -23.39% | 8.55% | -8.24% | 14.71% | 54.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 14.61% | 16.91% | -13.98% | 27.69% | 55.74% |
| Normalized Basic EPS | 14.64% | 16.93% | -13.84% | 12.23% | 55.74% |
| EPS Diluted | 14.61% | 16.91% | -13.98% | 27.69% | 55.74% |
| Normalized Diluted EPS | 14.64% | 16.93% | -13.84% | 12.23% | 55.74% |
| Average Basic Shares Outstanding | 48.35% | 13.33% | 1.59% | 1.46% | 1.17% |
| Average Diluted Shares Outstanding | 48.35% | 13.33% | 1.59% | 1.46% | 1.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |